Superintelligence and Synthetic Biology Are Merging— Creating Living Products.
Investing across the Colossal Biosciences ecosystem: the end-to-end platform for programmable biology.
Investing across the Colossal Biosciences ecosystem: the end-to-end platform for programmable biology.
01
De-extinction and species preservation
02
Ending the microplastics problem
03
AI and biological intelligence
04
In stealth
05
Future spinouts
A venture fund at the intersection of superintelligence and synthetic biology. NeoGenesis Capital finances the industrialization of biology, turning genetic code into living products across markets measured in the trillions.
01 Thesis
The highest-returning ventures of the last decade were not found.
They were incubated inside closed ecosystems, and access, not discovery, was the edge.
Anthropic. xAI. OpenAI. SpaceX. In each case, concentrated access to a generational founder’s ecosystem produced the defining companies of their era. The model is simple and repeatable: identify a generational builder, then invest across what they touch.
NeoGenesis Capital applies that architecture to programmable biology. Ben Lamm and George Church built an engine that reads, writes, edits, and scales living systems. The fund is designed to invest in the engine and in what it produces.
This is a deliberately concentrated, single-ecosystem strategy. The concentration is the thesis.
//////////////////////
company snapshot
CLSL LABS
Est. 2021
Colossal Biosciences is an end-to-end AI and genetic engineering platform that reads, models, writes, builds, and scales living systems across animals and microbes. 260 employees. 57 full-time PhDs.The technical moat is measurable: hundreds of simultaneous genetic edits in a single cell line at 90% or more efficiency, significantly more than any other known commercially available tool. Standard CRISPR achieves 2–10 edits.
recent stats
02 Platform
\\ The full stack for building with biology //
The operating system for programmable life. Colossal’s pipeline runs from ancient DNA to living animals, and de-extinction is its proving ground.
Colossal // de-extinction pipeline
Colossal proprietary tech
\\ gestated inside one platform //
//////////////////////
01 THESIS
The highest-returning ventures of the last decade were not found.
They were incubated inside closed ecosystems, and access, not discovery, was the edge.
Anthropic. xAI. OpenAI. SpaceX. In each case, concentrated access to a generational founder’s ecosystem produced the defining companies of their era. The model is simple and repeatable: identify a generational builder, then invest across what they touch.
NeoGenesis Capital applies that architecture to programmable biology. Ben Lamm and George Church built an engine that reads, writes, edits, and scales living systems. The fund is designed to invest in the engine and in what it produces.
This is a deliberately concentrated, single-ecosystem strategy. The concentration is the thesis.
company snapshot
CLSL LABS
Est. 2021
recent stats
****
Colossal Biosciences is an end-to-end AI and genetic engineering platform that reads, models, writes, builds, and scales living systems across animals and microbes. 260 employees. 57 full-time PhDs.The technical moat is measurable: hundreds of simultaneous genetic edits in a single cell line at 90% or more efficiency, significantly more than any other known commercially available tool. Standard CRISPR achieves 2–10 edits.
$635M+
$5T+
03
Capital raised
Estimated platform TAM
Source: EY-Parthenon
Announced spinouts
\\ The full stack for building with biology //
02 PLATFORM
The operating system for programmable life. Colossal’s pipeline runs from ancient DNA to living animals, and de-extinction is its proving ground.
Ancient DNA Extraction & Assembly
Ancestral State Reconstruction
Cryopreservation & Reanimation
DNA Synthesis
Assisted
DNA
Assembly
Artificial
Wombs
Genome Sequencing
Computational
& Comparative
Analysis
AI-Assisted Editing
Multiplex Gene Editing & Clustered Delivery
SCNT & iSCNT
Colossal proprietary tech
//
Colossal
de-extinction pipeline
\\ gestated inside one platform //
Built by Ben Lamm and George Church.
Platform anchor
Colossal’s de-extinction programs serve as demanding integration tests for capabilities with applications far beyond any one species. Every company below was gestated here.
Planetary remediation
Seven grams of microplastics sit in the average human brain alone, not counting other tissues like the liver and kidneys. Breaking is building a scalable solution at the source.
Biologic and enzymatic degradation of PET plastics without pretreatment or microplastic generation, in pilots with major apparel brands.
AI and biological intelligence
A predictive engine for biology: the third company gestated by Ben, George, and the Colossal ecosystem, after Form Bio and Breaking, and the first to reach unicorn status.
Founded by Ben Lamm and George Church to forecast how biological systems change (evolution, disease risk, system vulnerability) before they do.
New Synthetic Biology Technology
Every gestation opens a market, not a product line.
Ben and George continue to build new companies across synthetic biology. As each one spins out, NeoGenesis Capital is positioned to invest.
Form Bio, the platform’s first spinout (2022), predates the fund and is not a NeoGenesis investment.
\\ bringing industry giants together //
04 Leadership
NeoGenesis is led by partners with direct experience across science, venture creation, healthspan, and emerging technology.
\\ fund leadership //
Fortune’s “World’s 50 Greatest Leaders.” Founder and Executive Chairman of XPRIZE. Co-Founder of Fountain Life. Author of four bestsellers. Seed investor in Colossal Biosciences. MIT and Harvard Medical School.
Dr. Diamandis’s primary thought partner and operational lead across healthspan and life science initiatives. Founding team of Link Ventures’ Link-XPV Fund, an early-stage AI fund out of the Harvard and MIT ecosystem. Helped launch XPRIZE Healthspan. MS in Biotechnology and PhD in Cancer Biology, Georgetown University.
Entrepreneur, investor, actor, and producer. Has invested in and helped build over 30 brands. Co-founder of Caliwater. Producer of films and documentaries globally. Supports the shaping of the firm’s cultural identity and strategic relationships.
\\ platform architects //
Built Colossal from zero to $10.3 billion in four years. Serial deep-tech founder with multiple exits. Drives the operational velocity and capital strategy behind the most consequential platform in synthetic biology.
Co-Founder and CEO, Colossal Biosciences
The “Father of Synthetic Biology.” CRISPR pioneer. Professor at Harvard and MIT. 135+ patents. 17 university lab partnerships. Architect of the intellectual property engine behind every company in this ecosystem.
Co-Founder and Scientific Advisor, Colossal Biosciences
Disclosure // Colossal Biosciences
Ben Lamm and George Church lead Colossal Biosciences. Neither holds any economic interest in NeoGenesis Capital, receives any management fee or carried interest from the fund, or takes part in its investment decisions. They are named here as the founders of the platform the fund invests in.
Five years from founding to the largest privately held platform in synthetic biology. Every proof point below is public record.
\\ Portfolio, as seen in //
\\ Contact //
Get in touch. Tell us a bit about yourself and we’ll follow up directly.
